Wave Life Sciences tumbles after genetic disorder drug trial data misses expectations

Wave Life Sciences

03/09/2025 15:07

** Shares of drug developer Wave Life Sciences WVE.O fall 22% to $7.50

** Co posted interim data from its ongoing early-to-mid stage trial testing WVE-006 for the treatment of alpha-1 antitrypsin deficiency, a rare genetic disorder

** Co says patients who received multiple 200 mg doses reached protein levels that could lower their risk of liver and lung diseases

** Jones Trading analyst Catherine Novack in an mail response said that the "data are below investor expectations for a viable AATD therapy"

** "There's still hope Wave can improve with higher dose levels, although dose response between 200mg and 400mg was modest," Novack added

** During the trial one patient showed increased protein levels during an acute phase response caused by a kidney stone, co says

** As of last close, stock down 42% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))